Gattex (teduglutide) / Takeda - LARVOL DELTA

Letter to the editor: Interpreting pooled GLP-2 analogue effects in chronic intestinal failure transparency, attrition, and real-world generalisability. (PubMed, Clin Nutr ESPEN) - No abstract available

Journal • Real-world evidence • Gastrointestinal Disorder • Short Bowel Syndrome

Use of teduglutide in short bowel syndrome in infants, children and adolescents: Position paper of the working group "Chronic intestinal failure" of the Society for Paediatric Gastroenterology and Nutrition (GPGE) (PubMed, Z Gastroenterol) - "This position paper summarizes the current evidence on the efficacy and safety of teduglutide in children and provides practice-oriented recommendations from the expert group on the following aspects: Definition of relevant treatment goals (e.g., infusion-free days, enteral autonomy), criteria for indication, classification in the treatment algorithm, requirements for education, care, monitoring, and follow-up. The aim is to create a structured framework for the clinical use of teduglutide in children and adolescents."

Journal • Cardiovascular • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Infectious Disease • Pediatrics • Short Bowel Syndrome • Thrombosis

TED_ORG: Study on Short Bowel Syndrome (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Meyer Children's Hospital IRCCS

New trial • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System. (PubMed, Ther Adv Drug Saf) - "Humira (10,356 cases) was the most frequently reported drug, followed by Remicade (2223 cases), Avastin (1580 cases), Vedolizumab (1385 cases), Clozaril (1229 cases), and Accutane (1088 cases). Disproportionality analysis revealed that the top five drugs with the highest ROR and PRR were Accutane, Teduglutide, Lonsurf, Avastin, and Lynparza...The high volume of reports associated with certain drugs may reflect usage patterns, underlying disease conditions, or reporting behaviors. Caution should be exercised in clinical translation."

Adverse events • Journal • Gastrointestinal Disorder

An Advanced Human IBD Model for Predicting Drug Permeability, Safety, and Efficacy: A Next-Generation Platform for Translational Therapeutic Screening (ECCO-IBD 2026) - "It was applied to evaluate permeability, safety, and efficacy of IBD therapeutics, including teduglutide (TED), a GLP-2 analog, tested in free and reactive oxygen species (ROS)-sensitive nanoparticle forms, and budesonide using a similar NP system...The observed localized drug action and enhanced anti-inflammatory effects validate the potential of NP-based delivery systems to improve IBD treatment while minimizing systemic side effects. Overall, this immune-competent, cost-effective, and ethical platform offers a powerful alternative to animal models, accelerating the development of targeted therapies for IBD."

Clinical • Metastases • Inflammatory Bowel Disease • CCL20 • CXCL10 • CXCL8 • CXCL9 • IFNG • IL1B • IL6 • MUC2 • MUC5AC • TNFA

Systemic Pharmacokinetic Principles of Therapeutic Peptides. (PubMed, Clin Pharmacokinet) - "In summary, our results underscore that the systemic pharmacokinetics of peptide drugs generally follow size-related physiological scaling patterns and provide quantitative tools to facilitate translational assessments in the drug discovery process."

Journal • PK/PD data

Double-balloon enteroscopy evaluation and surveillance in patients with short bowel syndrome. (PubMed, Therap Adv Gastroenterol) - "DBE could be effective in exploring the residual small bowel (SB) entirely, in monitoring patients receiving teduglutide (TED) treatment and, if necessary, could be operative...DBE is feasible, safe, and effective in SBS patients. Total enteroscopy can be frequently achieved with a single approach in these patients, allowing easy diagnostic and oncologic surveillance for SB and colonic malignancy."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Disorder • Oncology • Short Bowel Syndrome

MANAGEMENT OF PROTRACTED CLOSTRIDIOIDES DIFFICILE INFECTION IN CHILDREN WITH GI-GVHD AFTER ALLOGENEIC HSCT: A SINGLE-CENTER PEDIATRIC EXPERIENCE (EBMT 2026) - "According to ECIL-10 recommendations, bezlotoxumab and fecal microbiota transplantation (FMT) may be considered in recurrent CDI after vancomycin or fidaxomicin therapy in high-risk patients...Persistent CDI was documented from day +55 despite intensive immunosuppression (cyclosporine A, corticosteroids, ruxolitinib, mesenchymal stromal cells, extracorporeal photopheresis, vedolizumab)...TA-TMA was confirmed and treated with ravulizumab... Management of CDI after allo-HSCT requires a comprehensive and highly individualized approach, as CDI frequently coexists with GI-GvHD and TA-TMA. CDI may exacerbate GI-GvHD, while immunosuppression increases infection severity. Protracted CDI can lead to long-lasting intestinal dysfunction requiring supportive interventions, including teduglutide."

Clinical • Bone Marrow Transplantation • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Pediatrics • Septic Shock • Transplantation Associated Thrombotic Microangiopathy

Low-digestible glucans promote rapid recovery from 5-fluorouracil-induced small intestinal villous atrophy while enhancing glucagon-like peptide-2 secretion in rats. (PubMed, Nutr Res) - "Although the glucagon-like peptide-2 (GLP-2) analog teduglutide can promote villus regeneration, its clinical application is limited. In summary, LDGs promote rapid recovery of small intestinal villi after chemotherapy-induced injury, possibly through enhanced GLP-2 secretion. Dietary LDGs may offer a novel nutritional intervention to support mucosal recovery in participants undergoing cancer chemotherapy."

Journal • Preclinical • Oncology

CROHNtrol – Local Combination Nanotherapy for Crohn’s Disease (ECCO-IBD 2026) - "CHRONtrol proposes an orally administered dual-action therapy that integrates budesonide and teduglutide into smart delivery systems, allowing their local action...After achieving the most synergistic combination, its performance will be tested in SAMP1/YitFc mouse models. Anticipated impact CHRONtrol will deliver proof-of-concept data for a first-in-class dual-action nanotherapy, supporting its future translation into a scalable, oral treatment with improved efficacy and safety for patients with CD."

Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease

GATTEX KAB: A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey) (clinicaltrials.gov) - P=N/A | N=600 | Recruiting | Sponsor: Takeda | Trial completion date: Dec 2026 ➔ Dec 2031 | Trial primary completion date: Dec 2026 ➔ Dec 2031

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome

Real-world efficacy of long-term teduglutide use in pediatric patients with short bowel syndrome. (PubMed, Intest Fail) - "10 patients permanently discontinued treatment at mean 62.59 (SD=55.55) weeks, 4 due to related AEs. Pediatric SBS patients experienced significant decreases in PS dependency, providing real-world evidence of teduglutide efficacy."

Journal • Real-world evidence • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome • Transplantation

Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms. (PubMed, J Clin Endocrinol Metab) - "We provide novel data on the efficacy of putative and established therapies in patient-derived GEP-NEN primary cultures. Our standardized platform for personalized drug screening and risk assessment in GEP-NEN primary cultures enables prediction of individual tumor treatment response in this orphan disease."

Journal • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • CDK4

A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome (clinicaltrials.gov) - P=N/A | N=12 | Not yet recruiting | Sponsor: Takeda

New trial • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Impact of teduglutide on pediatric short bowel syndrome: A systematic review and trial sequential meta-analysis. (PubMed, World J Gastrointest Surg) - "Teduglutide does not increase infection or gastrointestinal adverse event risk in pediatric SBS, but small sample sizes limit conclusions. Larger studies are needed."

Journal • Retrospective data • Gastrointestinal Disorder • Infectious Disease • Pain • Pediatrics • Respiratory Diseases • Short Bowel Syndrome

Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study. (PubMed, Pediatr Int) - P3 | "In the three patients with SBS-IF who weighed less than 10 kg, no new safety signals were observed following teduglutide treatment. Clinically meaningful reductions in PS were noted and there was no adverse impact on growth parameters."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Loss of GLP-2R signaling in Glp2r-/- mice increases the long-term severity of graft versus host disease. (PubMed, Mol Metab) - "Activation of GLP-2R signaling did not reduce the severity of experimental aGvHD, failing to replicate a previous study using an identical aGvHD protocol. Nevertheless, loss of GLP-2R signaling in transplant recipients decreased survival and increased bacteremia, implicating an essential role for endogenous GLP-2R signaling in maintaining barrier function in the context of immune-mediated gut epithelial injury."

Journal • Preclinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Inflammation • Inflammatory Bowel Disease • Transplantation

Impact of Teduglutide on Hospital Readmissions Among Patients with Short Bowel Syndrome at the University of Illinois Hospital & Health Sciences System (ASHP 2025) - No abstract available

Clinical • Gastrointestinal Disorder • Short Bowel Syndrome

Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina. (PubMed, World J Gastrointest Pharmacol Ther) - "This prospective real-world study demonstrated the effectiveness and safety of teduglutide in adult and pediatric patients with SBS in Argentina. The clinical response observed in both adults and pediatric patients was greater than that reported in phase 3 trials and was consistent with the results of other real-world studies."

Journal • Real-world evidence • Gastrointestinal Disorder • Pain • Pediatrics • Short Bowel Syndrome

Positive clinical outcomes associated with use of glucagon-like peptide-2 (GLP-2) analogues in patients with Intestinal Failure: a systematic review and meta-analysis. (PubMed, Clin Nutr ESPEN) - "Teduglutide appears to be an acceptable therapy, with a discontinuation rate of 14%. Early reports suggest similar benefits for emerging GLP-2 including glepaglutide and apraglutide."

Clinical data • Journal • Retrospective data • Gastrointestinal Disorder • Short Bowel Syndrome

Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance. (PubMed, Adv Ther) - P | "In this interim analysis of a 36-month PMS, teduglutide demonstrated an acceptable safety profile and promising effectiveness in patients with SBS."

Journal • P4 data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Pain • Pediatrics • Short Bowel Syndrome

3, 2, 1! From GLP-2 to GLP-1 analog over a 10-year journey. (PubMed, Endocrinol Diabetes Nutr (Engl Ed)) - "This allowed for a surgical reconstruction, after which she achieved full enteral autonomy, later developing grade 1 obesity. This case highlights the therapeutic potential of teduglutide as a bridging therapy and the remaining uncertainties regarding its long-term management."

Journal • Review • Gastrointestinal Disorder • Genetic Disorders • Obesity • Short Bowel Syndrome

Delayed presentation of a retained colonic segment in a child with intestinal failure on teduglutide. (PubMed, JPGN Rep) - "Despite relatively few reported side effects, there is a theoretical risk of proliferative complications. Here we present an intriguing case of a pediatric patient found to have a decade-long retained, discontinuous segment of colon from a surgical procedure performed in infancy, which became clinically significant after a period of treatment with teduglutide."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Multifactorial Kidney Transplant Failure in a Patient with Short-Bowel Syndrome (KIDNEY WEEK 2025) - "Previous studies have shown the benefit of diet modifications before and after transplant to reduce oxaluria. Teduglutide, a GLP-2 analog, has shown benefit in treating both SBS and its associated kidney failure in post transplant patients."

Clinical • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Calculi • Short Bowel Syndrome • Transplant Rejection • Transplantation

"Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey" (DGHO 2025) - "Our retrospective analysis suggests that teduglutide is safe and has activity in a fraction of patients with intestinal SR-aGvHD, which needs validation in a prospective trial."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology